Drug Pipeline

LY4395089 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12

Active Studies

Recruiting

Top Sponsors

Changes, 30 Days

What Changed in the Last 30 Days

Detected	Trial	Change
2026-05-20	NCT07483099 A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone)…	Recruitment opened
2026-05-20	NCT07483073 A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or…	Recruitment opened

New Trial Filings, Last 30 Days

First Posted	Trial	Phase	Status
2026-05-18	NCT07592572 A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants	Phase 1	Not Yet Recruiting

Active Studies by Phase

Phase 2

Phase 1

Active Trials

NCT ID	Title	Condition	Status
Phase 2
NCT07483073	A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or…	Colitis, Ulcerative	Recruiting
NCT07483099	A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone)…	Crohn Disease	Recruiting
Phase 1
NCT07592572	A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants	Healthy	Not Yet Recruiting

Sponsors Running LY4395089 Trials

Eli Lilly and Company (3)

Disease Areas

Crohn's Disease (2)

Get alerts when LY4395089 trials change

Status changes, date slips, and new filings — detected daily, delivered to your inbox.